Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
Andrés Poveda(Hospital Quirónsalud Barcelona), Nicolas Pécuchet, Alla Lisyanskaya(City Clinical Oncology Center), Jean‐Pierre Lotz, Rebecca Asher(The University of Sydney), Diane Provencher(Centre Hospitalier de l’Université de Montréal), Michael Friedländer(Prince of Wales Hospital), Tomasz Byrski(International Hereditary Cancer Center), Tomasz Huzarski(International Hereditary Cancer Center), Giovanni Scambia(Agostino Gemelli University Polyclinic), Alessandra Baldoni(Mario Negri Institute for Pharmacological Research), Elias Abdo Filho(Universidade de São Paulo), Andrew R. Clamp, Elizabeth Lowe(AstraZeneca (United States)), Jacob Korach(Tel Aviv University), Gabe S. Sonke(Oncode Institute), Manuel Rodrigues(Inserm), Tsveta Milenkova(AstraZeneca (United Kingdom)), Ignace Vergote(KU Leuven), Jacques Médioni, Frédèric Selle, Kenji Tamura(Unknown), Patricia Pautier(Université Paris-Saclay), Amit M. Oza(Ontario Institute for Cancer Research), Éric Pujade-Lauraine(Eau de Paris (France)), Isabelle Ray‐Coquard(Centre Léon Bérard), Philip Rowe(University of Strathclyde), Philipp Harter(Kliniken Essen-Mitte), Jonathan A. Ledermann(London Cancer), Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Mayu Yunokawa(Japanese Foundation For Cancer Research), Clare L. Scott(Walter and Eliza Hall Institute of Medical Research), Richard T. Penson(Massachusetts General Hospital), Anne Floquet(Institut Bergonié), Jae‐Hoon Kim(Bio-Medical Science (South Korea)), Nicoletta Colombo(University of Milano-Bicocca), Aleix Prat Aparicio, A. Poveda Velasco(Hospital Quirónsalud Barcelona), Maria Ornella Nicoletto, Laura Vidal Boixader, Tjoung-Won Park-Simon(German Society of Surgery), Fiona Nussey
Cited by 412
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k